VEGFA and wet macular degeneration: Standard of care for the treatment of neovascular age-related macular degeneration (nAMD) and visual impairment due to centre-involving diabetic macular oedema (DMO) is intravitreal anti-vascular endothelial growth factor (anti-VEGF) therapy [1, 2].